PDAC

This study tests a new drug (GFH375) combined with either another targeted therapy (cetuximab) or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if these combinations are safe and can shrink tumors. About 126 adults w…

This study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The goal is to find safe doses and see if the combinations shrink tumors. About 18…

This study tests a new drug, daraxonrasib, to see if it can stop pancreatic cancer from returning after surgery and chemotherapy. About 500 people who have had their tumor removed and finished chemo will either take the drug or just be watched. The goal is to see if the drug help…

This early-stage study tests an experimental drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V mutation. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 574 participants will …

This phase 3 trial tests a new drug called daraxonrasib, alone or with standard chemotherapy, for people with metastatic pancreatic cancer that has spread. About 900 adults with a specific RAS gene mutation will be randomly assigned to one of three treatment groups. The study aim…

This study tests two experimental drugs, IN10018 and RNK08954, given together to people with advanced solid tumors that have a specific KRAS G12D gene change. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or …

This study enrolls 5,000 people at high risk for pancreatic cancer to collect blood, pancreatic juice, and medical images over 10 years. Researchers will use this information to develop and test new methods for early detection, including AI-assisted analysis. Participants must be…